Sunday , March 26 2017
Home / Technology & Devices

Technology & Devices

Facial Recognition Software Helps Diagnose Rare Genetic Disease

Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and their collaborators, have successfully used facial recognition software to diagnose a rare, genetic disease in Africans, Asians and Latin Americans. The disease, 22q11.2 deletion syndrome, also known as DiGeorge syndrome and velocardiofacial syndrome, …

Read More »

Scripps Florida Scientists Develop New Drug Delivery Method for Cancer Therapy

JUPITER, FL – March 16, 2017 – Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors. The study, led by TSRI Associate Professor Christoph …

Read More »

Routine Blood Tests Can Help Measure A Patient’s Future Risk for Chronic Disease, New Study Finds

A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City finds that combining information from routine blood tests and age of primary care patients can create a score that measures future risk of chronic disease. This simple risk score, termed the Intermountain Chronic Disease …

Read More »

Allergan and Editas Announce CRISPR-Based Research and Development Deal for Rare Eye Diseases

DUBLIN and CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and development alliance …

Read More »

Study Confirms Accuracy of OncoCyte’s Blood Test for Early Detection of Lung Cancer

ALAMEDA, Calif., March 06, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported the successful completion of a critical step in the development of its lung cancer diagnostic test. While the key performance …

Read More »

Exonics Therapeutics Launches with Funding from CureDuchenne to Advance CRISPR/Cas9 Therapy for DMD

BOSTON, Feb. 27, 2017 (GLOBE NEWSWIRE) — Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies like CRISPR/Cas9 to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, today announced a commitment of $5 million in seed financing from CureDuchenne …

Read More »

New Assay May Lead to a Cure for Debilitating Inflammatory Joint Disease

Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at NYU Langone Medical Center and the University of Pittsburgh. Known as autoantibodies and produced by the immune system’s B cells, …

Read More »

OncoSec’s ImmunoPulse Shows Treatment Effect in Phase 2 Melanoma Study

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec’s investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), …

Read More »

X-Chem Expands its Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, …

Read More »

Horizon Discovery Signs a Master Service Agreement with Top Three Pharma Company

Cambridge, UK, 14 February 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Group”), the world leader in the application of gene editing technologies, today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company (the “Company”), extending support for their drug discovery …

Read More »